^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Blenrep (belantamab mafodotin-blmf)

    i
    Other names: GSK2857916, J6M0-mcMMAF, GSK 2857916, GSK-2857916, GSK916, GSK-916, GSK 916
    Company:
    GSK, Pfizer
    Drug class:
    Microtubule inhibitor, BCMA-targeted antibody-drug conjugate
    Related drugs:
    11d
    DREAMM-20: A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (clinicaltrials.gov)
    P1/2, N=153, Recruiting, GlaxoSmithKline | Phase classification: P1 --> P1/2 | N=55 --> 153
    Phase classification • Enrollment change
    |
    dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    12d
    GEM-BELA-VRd: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, PETHEMA Foundation | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • Blenrep (belantamab mafodotin-blmf)
    18d
    BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape. (PubMed, Semin Hematol)
    We then summarize the clinical development and distinguishing features of currently approved BCMA-targeted modalities-CAR T-cell therapies (ide-cel, cilta-cel), bispecific T-cell engagers (teclistamab, elranatamab, linvoseltamab), and the antibody-drug conjugate (belantamab mafodotin)-highlighting their efficacy, toxicity profiles, and practical positioning in relapsed/refractory MM. Finally, we review emerging resistance mechanisms, including γ-secretase-driven sBCMA elevation, ligand-rich APRIL/BAFF niches, and therapy-induced TNFRSF17 lesions, ranging from biallelic deletions to epitope-altering missense mutations and in-frame deletions within the BCMA extracellular domain. These insights inform rational strategies such as γ-secretase inhibition, dual-target CAR T-cells and bispecific T-cell engagers.
    Journal • IO biomarker
    |
    TNFRSF17 (TNF Receptor Superfamily Member 17)
    |
    Elrexfio (elranatamab-bcmm) • Blenrep (belantamab mafodotin-blmf) • Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel) • Tecvayli (teclistamab-cqyv) • Lynozyfic (linvoseltamab-gcpt)
    20d
    ISABELA: Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    dexamethasone • pomalidomide • Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf)
    26d
    DREAMM-10: A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) (clinicaltrials.gov)
    P3, N=520, Recruiting, GlaxoSmithKline | Trial completion date: Apr 2032 --> Mar 2031 | Trial primary completion date: Dec 2030 --> Mar 2031
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • Blenrep (belantamab mafodotin-blmf)
    2ms
    PrE1005: Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, PrECOG, LLC.
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Blenrep (belantamab mafodotin-blmf)
    2ms
    ALANIS: A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, GlaxoSmithKline | Trial completion date: Oct 2031 --> Feb 2032 | Initiation date: Dec 2025 --> Mar 2026 | Trial primary completion date: Apr 2027 --> Aug 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    bortezomib • cyclophosphamide • Blenrep (belantamab mafodotin-blmf)
    2ms
    Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    melphalan • Blenrep (belantamab mafodotin-blmf)
    2ms
    DREAMM 13: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (clinicaltrials.gov)
    P1, N=0, Withdrawn, GlaxoSmithKline | N=28 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Blenrep (belantamab mafodotin-blmf)
    3ms
    GEM-BELA-VRd: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, PETHEMA Foundation | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Dec 2025
    Enrollment closed • Trial completion date
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • Blenrep (belantamab mafodotin-blmf)
    3ms
    Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant (clinicaltrials.gov)
    P2, N=20, Suspended, Roswell Park Cancer Institute | Recruiting --> Suspended
    Trial suspension • Minimal residual disease
    |
    lenalidomide • Blenrep (belantamab mafodotin-blmf)
    3ms
    A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, GlaxoSmithKline
    New P2 trial
    |
    bortezomib • carfilzomib • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)